MCID: DYS009
MIFTS: 43

Dysthymic Disorder

Categories: Mental diseases

Aliases & Classifications for Dysthymic Disorder

MalaCards integrated aliases for Dysthymic Disorder:

Name: Dysthymic Disorder 12 44 15 73
Dysthymia 12 76 55 15

Classifications:



External Ids:

Disease Ontology 12 DOID:12139
ICD10 33 F34.1
ICD9CM 35 300.4
MeSH 44 D019263
NCIt 50 C34562
SNOMED-CT 68 78667006
UMLS 73 C0013415

Summaries for Dysthymic Disorder

Disease Ontology : 12 A mood disorder that involves the presence of a low mood almost daily over a span of at least two years.

MalaCards based summary : Dysthymic Disorder, also known as dysthymia, is related to atypical depressive disorder and depression. An important gene associated with Dysthymic Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Methyltestosterone and Testosterone enanthate have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and testes, and related phenotype is muscle.

Wikipedia : 76 Persistent Depressive Disorder (PDD), formerly known as dysthymia, is a mood disorder consisting of the... more...

Related Diseases for Dysthymic Disorder

Diseases related to Dysthymic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Related Disease Score Top Affiliating Genes
1 atypical depressive disorder 31.6 HTR2A HTR7 MAOA SLC6A4
2 depression 30.9 HTR2A MAOA SLC6A4
3 anxiety 30.4 HTR2A MAOA SLC6A4
4 personality disorder 30.4 HTR2A MAOA SLC6A4
5 major depressive disorder 30.4 GATA3 HTR2A MAOA SLC6A4
6 attention deficit-hyperactivity disorder 30.2 HTR2A MAOA SLC6A4
7 generalized anxiety disorder 30.2 HTR2A MAOA SLC6A4
8 obsessive-compulsive disorder 30.0 HTR2A MAOA SLC6A4
9 borderline personality disorder 29.8 HTR2A MAOA SLC6A4
10 panic disorder 29.8 HTR2A MAOA SLC6A4
11 alcohol dependence 29.8 HTR2A MAOA SLC6A4
12 endogenous depression 29.7 HTR2A HTR7 MAOA SLC6A4
13 schizophrenia 29.7 HTR2A HTR7 MAOA SLC6A4
14 chronic fatigue syndrome 29.7 HTR2A MAOA SLC6A4
15 bulimia nervosa 29.6 HTR2A SLC6A4
16 irritable bowel syndrome 29.5 HTR7 SLC6A4
17 pediatric autoimmune neuropsychiatric disorders associated with streptococcus infections 11.1
18 schizoid personality disorder 10.2 HTR2A PIR
19 dependent personality disorder 10.1 MAOA PIR
20 dopamine beta-hydroxylase deficiency, congenital 10.1 GATA3 MAOA
21 cyclothymic disorder 10.1
22 neurotic disorder 10.1
23 coronary artery vasospasm 10.1 HTR2A HTR7
24 drug-induced mental disorder 10.1 HTR2A HTR7
25 drug psychosis 10.1 HTR2A HTR7
26 alzheimer disease 10.0
27 avoidant personality disorder 10.0 MAOA SLC6A4
28 alcoholic psychosis 10.0 HTR2A SLC6A4
29 periodic limb movement disorder 10.0 HTR2A SLC6A4
30 social phobia 10.0 MAOA SLC6A4
31 separation anxiety disorder 10.0 HTR7 PIR
32 oppositional defiant disorder 10.0 MAOA SLC6A4
33 fibromyalgia 10.0 HTR2A SLC6A4
34 alacrima, achalasia, and mental retardation syndrome 10.0
35 epilepsy 10.0
36 antisocial personality disorder 10.0 MAOA SLC6A4
37 bipolar i disorder 9.9 HTR2A SLC6A4
38 postpartum depression 9.9 MAOA SLC6A4
39 conduct disorder 9.9 MAOA SLC6A4
40 pathological gambling 9.9 HTR2A MAOA SLC6A4
41 paranoid schizophrenia 9.9 HTR2A MAOA SLC6A4
42 serotonin syndrome 9.9 HTR2A MAOA SLC6A4
43 post-traumatic stress disorder 9.9 HTR2A MAOA SLC6A4
44 tobacco addiction 9.9 HTR2A MAOA SLC6A4
45 mood disorder 9.9 HTR2A MAOA SLC6A4
46 substance abuse 9.9 MAOA SLC6A4
47 sudden infant death syndrome 9.9 HTR2A MAOA SLC6A4
48 aging 9.9
49 polysubstance abuse 9.9
50 anorexia nervosa 9.9

Comorbidity relations with Dysthymic Disorder via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Adjustment Disorder Anxiety
Atrophic Gastritis Atypical Depressive Disorder
Avoidant Personality Disorder Benign Essential Hypertension
Borderline Personality Disorder Bronchitis
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Esophagitis
Familial Atrial Fibrillation Generalized Anxiety Disorder
Generalized Atherosclerosis Heart Disease
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Irritable Bowel Syndrome Ischemic Heart Disease
Major Depressive Disorder Mitral Valve Disease
Mood Disorder Narcissistic Personality Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Opioid Addiction Oral Candidiasis
Osteoarthritis Osteoporosis
Paralytic Ileus Parkinson Disease, Late-Onset
Peripheral Vascular Disease Personality Disorder
Postinflammatory Pulmonary Fibrosis Post-Traumatic Stress Disorder
Postural Orthostatic Tachycardia Syndrome Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Dysthymic Disorder:



Diseases related to Dysthymic Disorder

Symptoms & Phenotypes for Dysthymic Disorder

MGI Mouse Phenotypes related to Dysthymic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.02 ELP1 GATA3 HTR2A MFSD8 SLC6A4

Drugs & Therapeutics for Dysthymic Disorder

Drugs for Dysthymic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4 58-18-4 6010
2
Testosterone enanthate Approved Phase 4 315-37-7 9416
3
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
4
Testosterone Approved, Investigational Phase 4 58-22-0 6013
5
Citalopram Approved Phase 4,Phase 2,Phase 3 59729-33-8 2771
6
Sertraline Approved Phase 4,Phase 2,Phase 3 79617-96-2 68617
7
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
8
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-61-6, 62-31-7 681
9
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-41-2 439260
10
Fluoxetine Approved, Vet_approved Phase 4,Phase 2,Phase 3 54910-89-3 3386
11
Bupropion Approved Phase 4,Phase 2,Phase 3 34841-39-9, 34911-55-2 444
12
Armodafinil Approved, Investigational Phase 4 112111-43-0
13
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
14
Imipramine Approved Phase 4 50-49-7 3696
15
Paroxetine Approved, Investigational Phase 4,Phase 2 61869-08-7 43815
16
Donepezil Approved Phase 4 120014-06-4 3152
17
Peppermint oil Approved, Investigational Phase 4 8006-90-4
18
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
19
Peppermint Approved Phase 4
20 Nutmeg Approved Phase 4
21
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22 Antineoplastic Agents, Hormonal Phase 4
23 Testosterone 17 beta-cypionate Phase 4
24 Anabolic Agents Phase 4
25 Androgens Phase 4
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
27 Hormone Antagonists Phase 4
28 Hormones Phase 4
29 Serotonin Agents Phase 4,Phase 2,Phase 3
30 Autonomic Agents Phase 4,Phase 2,Phase 1
31 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Parasympatholytics Phase 4,Phase 2
33 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Cholinergic Agents Phase 4,Phase 2,Phase 1
35 Cholinergic Antagonists Phase 4,Phase 2
36 Muscarinic Antagonists Phase 4,Phase 2
37 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3
38 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3
39 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Not Applicable
41 Antiparkinson Agents Phase 4,Phase 2,Not Applicable
42 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
44 Duloxetine Hydrochloride Phase 4,Not Applicable
45 Dopamine Agents Phase 4,Phase 2,Phase 3,Not Applicable
46 Analgesics Phase 4,Not Applicable
47 Monoamine Oxidase Inhibitors Phase 4
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
49 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3
50 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
2 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
3 Duloxetine Treatment in Elderly With Dysthymia Completed NCT01852383 Phase 4 Duloxetine
4 Wellbutrin XL for Dysthymic Disorder Completed NCT00225251 Phase 4 bupropion XL
5 Escitalopram in the Treatment of Dysthymic Disorder, Double Blind Completed NCT00220701 Phase 4 Lexapro (escitalopram)
6 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4 armodafinil;placebo
7 Duloxetine for Chronic Depression: a Double-blind Study Completed NCT00360724 Phase 4 Duloxetine (Cymbalta)
8 Desvenlafaxine vs. Placebo Treatment of Chronic Depression Completed NCT01537068 Phase 4 Desvenlafaxine;Placebo
9 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
10 Treatment of Depression Following Multiple Brain Tests Completed NCT00296777 Phase 4 Escitalopram;Bupropion;Imipramine
11 Dichotic Listening as a Predictor of Medication Response in Depression Completed NCT00296725 Phase 4 Fluoxetine;Imipramine
12 Are Two Antidepressants a Good Initial Treatment for Depression? Completed NCT00296712 Phase 4 escitalopram + bupropion
13 Dichotic Listening as a Predictor of Medication Response in Depression Completed NCT00404755 Phase 4 escitalopram;bupropion;imipramine
14 Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
15 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
16 A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression Completed NCT00296699 Phase 4 Duloxetine
17 Combination Treatment Study for Memory Impairment and Depression Completed NCT01658228 Phase 4 Donepezil;Placebo;Citalopram;Venlafaxine
18 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
19 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults Recruiting NCT01973283 Phase 4 Antidepressant Medication
20 L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults Recruiting NCT03761030 Phase 4 L-Dopa;Placebo Oral Tablet
21 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
22 Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction Terminated NCT00398632 Phase 4 Duloxetine
23 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
24 A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults Withdrawn NCT01942187 Phase 4 Aripiprazole;Bupropion
25 A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Completed NCT01447602 Phase 3
26 A Stepped Care Model of Adolescent Depression Treatment in Primary Care Completed NCT01443715 Phase 2, Phase 3
27 Treatment of Adolescent Suicide Attempters (TASA) Completed NCT00080158 Phase 2, Phase 3 fluoxetine;sertraline;citalopram;escitalopram;bupropion;mirtazapine;venlafaxine;lithium
28 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
29 Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder Completed NCT00707980 Phase 3 Vortioxetine
30 A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND} Active, not recruiting NCT02358343 Phase 3 Antidepressant Drug Therapy
31 Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia Not yet recruiting NCT03805152 Phase 3 Neuronox(R);Dysport (R)
32 Effects of Therapist Behavior on the Treatment of Depressed Adolescents Unknown status NCT00073359 Phase 1, Phase 2
33 A Study of Omega-3 as a Treatment for Major Depression Unknown status NCT00238758 Phase 2 Omega-3 Polyunsaturated Fatty Acids
34 The Efficacy of Parent Involvement in the Treatment of Adolescent Depression Completed NCT00883519 Phase 1, Phase 2
35 New Approaches to Cocaine Abuse Medications (A) - 6 Completed NCT00000271 Phase 2 Desipramine;Placebo
36 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
37 Computerized Information-Processing Bias Retraining in Depressed Adolescents Completed NCT01147913 Phase 2
38 A Safety, Efficacy and Tolerability Study of SEP-225289 Completed NCT00584974 Phase 2 SEP-225289;SEP-225289;Venlafaxine;placebo
39 Group Interpersonal Psychotherapy for Depressed Adolescents in School-based Clinics Completed NCT00270244 Phase 2
40 Group Therapy for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
41 Bringing What Works to Youth in Corrections: A Trauma Intervention Completed NCT01560728 Phase 1, Phase 2
42 A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes Completed NCT02053272 Phase 2 GWP42004;Placebo
43 Smoking Cessation for Depressed Smokers Active, not recruiting NCT00494728 Phase 1, Phase 2 Nicotine Replacement Therapy
44 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Enrolling by invitation NCT02458690 Phase 2 Antidepressant Medications
45 Interpersonal Psychotherapy for Depressed Adolescents and Parents Completed NCT00619411 Phase 1
46 Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression Completed NCT00356304 Phase 1
47 Evaluating a Novel Internet Intervention for Persons With Epilepsy and Depression Unknown status NCT02791724 Not Applicable
48 Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression Unknown status NCT01473615 Not Applicable
49 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Unknown status NCT02707848
50 Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence Unknown status NCT01528748

Search NIH Clinical Center for Dysthymic Disorder

Cochrane evidence based reviews: dysthymic disorder

Genetic Tests for Dysthymic Disorder

Anatomical Context for Dysthymic Disorder

MalaCards organs/tissues related to Dysthymic Disorder:

41
Brain, Temporal Lobe, Testes, Thyroid, Monocytes, Amygdala

Publications for Dysthymic Disorder

Articles related to Dysthymic Disorder:

(show top 50) (show all 412)
# Title Authors Year
1
The association between lifetime cannabis use and dysthymia across six birth decades. ( 29605793 )
2018
2
GET.HAPPY - Acceptance of an internet-based self-management positive psychology intervention for adult primary care patients with mild and moderate depression or dysthymia: A pilot study. ( 30135766 )
2018
3
Affective Personality Traits in Olfactory Dysfunction: the Role of Dysthymia and Arousal. ( 30220958 )
2018
4
Changes in cytokine and chemokine expression distinguish dysthymic disorder from major depression and healthy controls. ( 27992767 )
2017
5
Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. ( 27554483 )
2017
6
Prescribing patterns of psychotropic medications and clinical features in patients with major depressive disorder with and without comorbid dysthymia in China. ( 27759189 )
2017
7
Corrigendum to "Prevalence and correlates of major depressive disorder and dysthymia in an eleven-year follow-up - Results from the Finnish Health 2011 Survey" [J. Affect. Disord. 173 (2015) 73-80]. ( 27866045 )
2017
8
Temporal relationship between dysthymia and temporomandibular disorder: a population-based matched case-control study in Taiwan. ( 28148250 )
2017
9
Cognitive Vulnerability in Patients with Generalized Anxiety Disorder, Dysthymic Disorder and Normal Individuals. ( 27045393 )
2016
10
Motivation for change as a predictor of treatment response for dysthymia. ( 27112812 )
2016
11
The validity of dysthymia to predict clinical depressive symptoms as measured by the Hamilton Depression Scale at the 5-year follow-up of patients with first episode depression. ( 27181030 )
2016
12
Dysthymia increases the risk of temporomandibular disorder: A population-based cohort study (A STROBE-Compliant Article). ( 27442660 )
2016
13
The Effect of Combining Mindfulness-Based Cognitive ‎Therapy with Pharmacotherapy on ‎Depression and Emotion ‎Regulation of Patients with Dysthymia: A Clinical Study. ( 27928248 )
2016
14
Assessment of Quality of Life (QOL) in Obsessive Compulsive Disorder (OCD) and Dysthymic Disorder (DD): A Comparative Study. ( 26155540 )
2015
15
Prevalence and correlates of major depressive disorder and dysthymia in an eleven-year follow-up--results from the Finnish Health 2011 Survey. ( 25462399 )
2015
16
Improving work outcomes of dysthymia (persistent depressive disorder) in an employed population. ( 25892151 )
2015
17
WITHDRAWN: Drugs versus placebo for dysthymia. ( 26087170 )
2015
18
Which is A More Debilitating Disorder Schizophrenia or Dysthymia? - A Comparative Study. ( 26155539 )
2015
19
Frontoparietal function in young people with dysthymic disorder (DSM-5: Persistent depressive disorder) during spatial working memory. ( 24709020 )
2014
20
The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? ( 24270481 )
2014
21
Relationship of quality of life with disability grade in obsessive compulsive disorder and dysthymic disorder. ( 25191009 )
2014
22
An open treatment trial of duloxetine in elderly patients with dysthymic disorder. ( 25177490 )
2014
23
Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: A comparison with standard treatment. ( 25140585 )
2014
24
Dysthymic disorder in the elderly population. ( 24152873 )
2014
25
Refining a complex diagnostic construct: subtyping Dysthymia with the Shedler-Westen Assessment Procedure-II. ( 24120405 )
2014
26
Systemic couple therapy for dysthymia. ( 24377406 )
2014
27
Anxiety and dysthymia: local prevalence estimates based on drug prescriptions by general practitioners in Turin (Italy). ( 24763444 )
2014
28
L-acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( 23428336 )
2013
29
Controlled randomized clinical trial of spirituality integrated psychotherapy, cognitive-behavioral therapy and medication intervention on depressive symptoms and dysfunctional attitudes in patients with dysthymic disorder. ( 24516853 )
2013
30
An examination of generalized anxiety disorder and dysthymic disorder by latent class analysis. ( 24020863 )
2013
31
Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study. ( 23466114 )
2013
32
Efficacy of add-on deep transcranial magnetic stimulation in comorbid alcohol dependence and dysthymic disorder: three case reports. ( 23724355 )
2013
33
The relationship of dysthymia, minor depression, and gender to changes in smoking for current and former smokers: longitudinal evaluation in the U.S. population. ( 22809897 )
2013
34
Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. ( 22963896 )
2013
35
Antidepressants normalize the default mode network in patients with dysthymia. ( 23389382 )
2013
36
The epidemiological modelling of dysthymia: application for the Global Burden of Disease Study 2010. ( 23806588 )
2013
37
Clinical features of patients with dysthymia in a large cohort of Han Chinese women with recurrent major depression. ( 24386213 )
2013
38
Are there temperament differences between major depression and dysthymic disorder in adolescent clinical outpatients? ( 21839431 )
2012
39
The categorisation of dysthymic disorder: can its constituents be meaningfully apportioned? ( 22835850 )
2012
40
Are there meaningful differences between major depressive disorder, dysthymic disorder, and their subthreshold variants? ( 22922240 )
2012
41
Dysthymia and depression increase risk of dementia and mortality among older veterans. ( 21597358 )
2012
42
Abnormal functional brain asymmetry in depression: evidence of biologic commonality between major depression and dysthymia. ( 22397909 )
2012
43
Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. ( 21536001 )
2011
44
Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. ( 21869696 )
2011
45
Dysthymia in a cross-cultural perspective. ( 21088583 )
2011
46
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. ( 21527126 )
2011
47
Dysthymia and apathy: diagnosis and treatment. ( 21747995 )
2011
48
A comparison of the clinical characteristics of Chinese patients with recurrent major depressive disorder with and without dysthymia. ( 21824660 )
2011
49
Tachyphylaxis/tolerance to antidepressants in treatment of dysthymia: results of a retrospective naturalistic chart review study. ( 21851459 )
2011
50
Can you recommend anything for dysthymia? ( 22125827 )
2011

Variations for Dysthymic Disorder

Expression for Dysthymic Disorder

Search GEO for disease gene expression data for Dysthymic Disorder.

Pathways for Dysthymic Disorder

GO Terms for Dysthymic Disorder

Cellular components related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of presynaptic membrane GO:0099056 8.96 HTR2A SLC6A4
2 integral component of postsynaptic membrane GO:0099055 8.62 HTR2A SLC6A4

Biological processes related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.43 GATA3 HTR2A SLC6A4
2 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.32 HTR2A HTR7
3 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.16 HTR2A HTR7
4 phosphatidylinositol 3-kinase signaling GO:0014065 8.96 GATA3 HTR2A
5 vasoconstriction GO:0042310 8.62 HTR7 SLC6A4

Molecular functions related to Dysthymic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.16 HTR2A HTR7
2 G protein-coupled serotonin receptor activity GO:0004993 8.96 HTR2A HTR7
3 serotonin binding GO:0051378 8.62 HTR2A SLC6A4

Sources for Dysthymic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....